AR053579A1 - Tratamiento de la enfermedad inflamatoria intestinal (eii) - Google Patents
Tratamiento de la enfermedad inflamatoria intestinal (eii)Info
- Publication number
- AR053579A1 AR053579A1 ARP060101467A ARP060101467A AR053579A1 AR 053579 A1 AR053579 A1 AR 053579A1 AR P060101467 A ARP060101467 A AR P060101467A AR P060101467 A ARP060101467 A AR P060101467A AR 053579 A1 AR053579 A1 AR 053579A1
- Authority
- AR
- Argentina
- Prior art keywords
- ibd
- treatment
- inflammatory disease
- intestinal inflammatory
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Tratamiento de la EII, especialmente la colitis ulcerativa (CU), con un anticuerpo que se une al CD2theta. Reivindicacion 1: Un procedimiento para tratar los casos moderados-graves de la enfermedad inflamatoria intestinal (EII) en un sujeto humano que consiste en administrar al paciente una cantidad eficaz de un anticuerpo del CD20 y cuyo resultado es una respuesta clínica o la remision de la enfermedad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67190205P | 2005-04-15 | 2005-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053579A1 true AR053579A1 (es) | 2007-05-09 |
Family
ID=36685736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101467A AR053579A1 (es) | 2005-04-15 | 2006-04-12 | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060233797A1 (es) |
EP (1) | EP1871414A1 (es) |
JP (1) | JP2008536855A (es) |
KR (1) | KR20070122543A (es) |
CN (1) | CN101184507A (es) |
AR (1) | AR053579A1 (es) |
AU (1) | AU2006236816A1 (es) |
BR (1) | BRPI0612321A2 (es) |
CA (1) | CA2605020A1 (es) |
IL (1) | IL186151A0 (es) |
MX (1) | MX2007012667A (es) |
NO (1) | NO20075845L (es) |
RU (1) | RU2007142188A (es) |
TW (1) | TW200714291A (es) |
WO (1) | WO2006113308A1 (es) |
ZA (1) | ZA200708850B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL146005A0 (en) | 1999-05-07 | 2002-07-25 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
PL1912675T3 (pl) | 2005-07-25 | 2014-10-31 | Emergent Product Dev Seattle | Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20 |
WO2008125903A2 (en) * | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
PL2178916T3 (pl) | 2007-07-31 | 2015-08-31 | Regeneron Pharma | Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania |
EP2262509A4 (en) * | 2008-03-07 | 2012-02-22 | Lawrence Bernstein | GALLIUM COMPOUNDS AND METHOD OF USE FOR THE TREATMENT OF INFLAMMATORY ENDURANCE |
WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US8206940B2 (en) * | 2008-05-15 | 2012-06-26 | Tufts University | Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US8440195B2 (en) | 2010-11-12 | 2013-05-14 | National University Corporation Chiba University | Inhibition of CD69 for treatment of inflammatory conditions |
BR112013026828A2 (pt) | 2011-04-21 | 2016-11-29 | Bristol Myers Squibb Co | polipeptídeos de anticorpo que antagonizam cd40 |
WO2013090989A1 (en) * | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
CN103149371B (zh) * | 2013-02-26 | 2015-12-23 | 哈药慈航制药股份有限公司 | 生物标记物在制备预测5-氨基水杨酸治疗溃疡性结肠炎的反馈响应药物中的应用 |
EP3054996B1 (en) | 2013-10-07 | 2023-06-21 | IGL Pharma, Inc. | Process for preparing high purity therapeutic bone agents |
US10435475B2 (en) * | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
WO2018102552A1 (en) * | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
JP2020514323A (ja) | 2017-02-06 | 2020-05-21 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物と方法 |
US20210325387A1 (en) * | 2017-07-17 | 2021-10-21 | The Broad Institute, Inc. | Cell atlas of the healthy and ulcerative colitis human colon |
JP7339262B2 (ja) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Pac1抗体及びその使用 |
CN112771077A (zh) | 2018-08-31 | 2021-05-07 | 瑞泽恩制药公司 | 针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略 |
US11535655B2 (en) * | 2019-12-06 | 2022-12-27 | Cheer Global Limited | Method of treating inflammatory bowel disease |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
WO1994011026A2 (en) * | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
AU8296098A (en) * | 1997-07-08 | 1999-02-08 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
IL141349A0 (en) * | 1998-08-11 | 2002-03-10 | Idec Pharma Corp | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 anti-body |
US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
AU761516B2 (en) * | 1998-11-09 | 2003-06-05 | Biogen Inc. | Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants |
EP1035172A3 (en) * | 1999-03-12 | 2002-11-27 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
US7074403B1 (en) * | 1999-06-09 | 2006-07-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
US6100245A (en) * | 1999-09-07 | 2000-08-08 | Mcneil-Ppc, Inc. | Use of simethicone to treat ulcerative colitis |
US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
EP1229935A1 (en) * | 1999-11-08 | 2002-08-14 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
US20030185796A1 (en) * | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
US20020009427A1 (en) * | 2000-03-24 | 2002-01-24 | Wolin Maurice J. | Methods of therapy for non-hodgkin's lymphoma |
WO2001074388A1 (en) * | 2000-03-31 | 2001-10-11 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
LT2857516T (lt) * | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
EP1286692A4 (en) * | 2000-04-25 | 2004-11-17 | Idec Pharma Corp | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM |
JP2003535907A (ja) * | 2000-06-22 | 2003-12-02 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法 |
CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
WO2002072636A2 (en) * | 2000-12-28 | 2002-09-19 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
ATE507839T1 (de) * | 2001-04-02 | 2011-05-15 | Genentech Inc | Kombinationstherapie |
US7718387B2 (en) * | 2001-09-20 | 2010-05-18 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
WO2003035835A2 (en) * | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003208415B2 (en) * | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
US20030219818A1 (en) * | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
NZ568769A (en) * | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
AR042485A1 (es) * | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
UA99933C2 (ru) * | 2003-04-09 | 2012-10-25 | Дженентек, Инк. | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2005017529A1 (en) * | 2003-07-29 | 2005-02-24 | Genentech, Inc. | Assay for human anti cd20 antibodies and uses therefor |
US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
JP2007504138A (ja) * | 2003-08-29 | 2007-03-01 | ジェネンテック・インコーポレーテッド | 眼疾患の治療法 |
AU2004305560A1 (en) * | 2003-12-19 | 2005-07-07 | Genentech, Inc. | Detection of CD20 in therapy of autoimmune diseases |
BRPI0510224A (pt) * | 2004-05-05 | 2007-10-23 | Genentech Inc | métodos de prevenção de doença autoimunológica e artigo industrializado |
-
2006
- 2006-04-12 AR ARP060101467A patent/AR053579A1/es not_active Application Discontinuation
- 2006-04-13 MX MX2007012667A patent/MX2007012667A/es not_active Application Discontinuation
- 2006-04-13 JP JP2008506671A patent/JP2008536855A/ja not_active Withdrawn
- 2006-04-13 WO PCT/US2006/013780 patent/WO2006113308A1/en active Application Filing
- 2006-04-13 CA CA002605020A patent/CA2605020A1/en not_active Abandoned
- 2006-04-13 US US11/403,462 patent/US20060233797A1/en not_active Abandoned
- 2006-04-13 BR BRPI0612321-0A patent/BRPI0612321A2/pt not_active IP Right Cessation
- 2006-04-13 ZA ZA200708850A patent/ZA200708850B/xx unknown
- 2006-04-13 KR KR1020077026455A patent/KR20070122543A/ko not_active Application Discontinuation
- 2006-04-13 RU RU2007142188/14A patent/RU2007142188A/ru not_active Application Discontinuation
- 2006-04-13 EP EP06740918A patent/EP1871414A1/en not_active Withdrawn
- 2006-04-13 CN CNA2006800185302A patent/CN101184507A/zh active Pending
- 2006-04-13 AU AU2006236816A patent/AU2006236816A1/en not_active Abandoned
- 2006-04-14 TW TW095113504A patent/TW200714291A/zh unknown
-
2007
- 2007-09-20 IL IL186151A patent/IL186151A0/en unknown
- 2007-11-14 NO NO20075845A patent/NO20075845L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0612321A2 (pt) | 2010-11-03 |
JP2008536855A (ja) | 2008-09-11 |
AU2006236816A1 (en) | 2006-10-26 |
RU2007142188A (ru) | 2009-05-20 |
IL186151A0 (en) | 2008-01-20 |
WO2006113308A1 (en) | 2006-10-26 |
CA2605020A1 (en) | 2006-10-26 |
NO20075845L (no) | 2008-01-14 |
MX2007012667A (es) | 2007-12-13 |
EP1871414A1 (en) | 2008-01-02 |
KR20070122543A (ko) | 2007-12-31 |
ZA200708850B (en) | 2009-03-25 |
CN101184507A (zh) | 2008-05-21 |
TW200714291A (en) | 2007-04-16 |
WO2006113308A8 (en) | 2007-01-18 |
US20060233797A1 (en) | 2006-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053579A1 (es) | Tratamiento de la enfermedad inflamatoria intestinal (eii) | |
BR112012012610A2 (pt) | terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma | |
CL2021002769A1 (es) | Anticuerpos de unión a vista (divisional solicitud n° 201902610) | |
PA8782201A1 (es) | Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
MA46219A (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
MX2018009738A (es) | Anticuerpos monoclonales de proteína ns1 anti-virus del dengue. | |
UY33144A (es) | Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana | |
Komrokji et al. | Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data | |
BR112015028244A2 (pt) | Imunoconjugado que se liga ao folr1 e seu uso | |
ATE460940T1 (de) | Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen | |
CL2011000099A1 (es) | Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria. | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
WO2022026360A3 (en) | Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use | |
WO2014169011A3 (en) | Methods for treating immune diseases | |
EA200800948A1 (ru) | Биотиндиаминопроизводные и их конъюгаты с макроциклическими хелатирующими реагентами | |
BR112022017110A2 (pt) | Composições e uso das mesmas | |
EA202190755A1 (ru) | Агенты для терапии и диагностики рака | |
Min et al. | Geriatric Assessment Predicts Non-Fatal Toxicities and Survival for Intensively Treated Elderly Acute Myeloid Leukemia: A Prospective Study | |
Peixoto | First report of gouty arthritis in a patient with gout: case report | |
SG11201901435UA (en) | Monoclonal antibody against melk and utilization thereof | |
Taylor et al. | Physiological correlates of simulated sprint-distance triathlon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |